Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype

被引:178
作者
Arnott, IDR [1 ]
Landers, CJ
Nimmo, EJ
Drummond, HE
Smith, BKR
Targan, SR
Satsangi, J
机构
[1] Univ Edinburgh, Western Gen Hosp, Gastrointestinal Unit, Dept Med Sci,Sch Clin & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Cedars Sinai Med Ctr, Inflammatory Bowel Dis Res, Los Angeles, CA USA
关键词
D O I
10.1111/j.1572-0241.2004.40417.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND AND AIMS: Antibodies directed against the porin protein C of Escherichia coli (anti-OmpC) and Pseudomonas fluorescens (anti-I2) have recently been described in Crohn's disease (CD). Those directed against Saccharomyces cerevisiae (ASCA) and the perinuclear component of neutrophils (pANCA) have been more widely studied and may be of diagnostic importance. We aimed to assess the frequency of anti-OmpC, anti-I2, ASCA, and pANCA, in an independent Scottish CD cohort, establish phenotypic associations, and compare with a U.S. cohort. METHODS: One hundred and forty-two well-characterized CD patients (76 females, median age 39 yr (17-88)) were studied. CD was classified by the Vienna classification. Sera were assayed for anti-OmpC, anti-I2, ASCA, and pANCA. Allele specific primers were used for NOD2/CARD15 genotyping. RESULTS: Anti-OmpC, anti-I2, ASCA, and pANCA were present in sera from 37%, 52%, 39%, and 14% of CID patients, respectively. Multivariate analysis demonstrated independent associations of anti-OmpC to be progression of disease type (p = 0.005) and long disease duration (p = 0.002), and those of anti-I2 to be long disease duration (p = 0.002) and the need for surgery (p = 0.033). ASCA were associated with disease progression (p < 0.001). When the presence and magnitude of all antibody responses were considered, reactivity to microbial components was associated with long disease duration (p < 0.001), progression of disease type (p < 0.001), penetrating disease (p = 0.008), small bowel disease (p < 0.02), and the need for surgery (p < 0.001). There was no association of antibody status to NOD2/CARD15 genotype. CONCLUSION: Reactivity to microbial components is associated with severe CD characterized by small bowel involvement, frequent disease progression, longer disease duration, and greater need for intestinal surgery.
引用
收藏
页码:2376 / 2384
页数:9
相关论文
共 49 条
  • [41] Dysbiosis in inflammatory bowel disease
    Tamboli, CP
    Neut, C
    Desreumaux, P
    Colombel, JF
    [J]. GUT, 2004, 53 (01) : 1 - 4
  • [42] Anti-Saccharomyces cerevisiae antibodies:: A stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment
    Teml, A
    Kratzer, V
    Schneider, B
    Lochs, H
    Norman, GL
    Gangl, A
    Vogelsang, H
    Reinisch, W
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (10) : 2226 - 2231
  • [43] Subclinical intestinal inflammation: An inherited abnormality in Crohn's disease relatives?
    Thjodleifsson, B
    Sigthorsson, G
    Cariglia, N
    Reynisdottir, I
    Gudbjartsson, DF
    Kristjansson, K
    Meddings, JB
    Gudnason, V
    Wandall, JH
    Andersen, LP
    Sherwood, R
    Kjeld, M
    Oddsson, E
    Gudjonsson, H
    Bjarnason, I
    [J]. GASTROENTEROLOGY, 2003, 124 (07) : 1728 - 1737
  • [44] Long-term treatment of ulcerative colitis with ciprofloxacin:: A prospective, double-blind, placebo-controlled study
    Turunen, UM
    Färkkilä, MA
    Hakala, K
    Seppälä, K
    Sivonen, A
    Ögren, M
    Vuoristo, M
    Valtonen, VV
    Miettinen, TA
    [J]. GASTROENTEROLOGY, 1998, 115 (05) : 1072 - 1078
  • [45] Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics
    Vasiliauskas, EA
    Kam, LY
    Karp, LC
    Gaiennie, J
    Yang, H
    Targan, SR
    [J]. GUT, 2000, 47 (04) : 487 - 496
  • [46] Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup
    Vasiliauskas, EA
    Plevy, SE
    Landers, CJ
    Binder, SW
    Ferguson, DM
    Yang, HY
    Rotter, JI
    Vidrich, A
    Targan, SR
    [J]. GASTROENTEROLOGY, 1996, 110 (06) : 1810 - 1819
  • [47] Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability:: A study in IBD families
    Vermeire, S
    Peeters, M
    Vlietinck, R
    Joossens, S
    Den Hond, E
    Bulteel, V
    Bossuyt, X
    Geypens, B
    Rutgeerts, P
    [J]. INFLAMMATORY BOWEL DISEASES, 2001, 7 (01) : 8 - 15
  • [48] Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease
    Vermeire, S
    Joossens, S
    Peeters, M
    Monsuur, F
    Marien, G
    Bossuyt, X
    Groenen, P
    Vlietinck, R
    Rutgeerts, P
    [J]. GASTROENTEROLOGY, 2001, 120 (04) : 827 - 833
  • [49] ULCERATIVE-COLITIS - A GENETICALLY HETEROGENEOUS DISORDER DEFINED BY GENETIC (HLA CLASS-II) AND SUBCLINICAL (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) MARKERS
    YANG, HY
    ROTTER, JI
    TOYODA, H
    LANDERS, C
    TYAN, D
    MCELREE, CK
    TARGAN, SR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (02) : 1080 - 1084